Signature Equity Partners’s First Trust NYSE Arca Biotechnology Index Fund FBT Stock Holding History

Signature Equity Partners’s Portfolio FBT Stock Details FBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.93K	Sell	32 -99	-76%	-$21.3K	﹤0.01%	880
2026 Q1	$26.3K	Buy	131 +3	+2%	+$621	0.01%	579
2025 Q4	$26.4K	Buy	+128	New	+$25.6K	0.01%	563

Other funds holding FBT

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bessemer Group Woodbridge, New Jersey $72.7B AUM 39.36% 1-Year Est. Return

BFG

Berger Financial Group Plymouth, Minnesota $1.96B AUM 20.58% 1-Year Est. Return

Signature Equity Partners's FBT Position: Q2 2026 in Review

Signature Equity Partners reduced its First Trust NYSE Arca Biotechnology Index Fund (FBT) stake by 76% in Q2 2026, selling an estimated $21.3K and leaving 32 shares worth $7.93K. The position accounts for ﹤0.01% of the portfolio, ranked #880.

Signature Equity Partners first reported a position in FBT in Q4 2025 and has held it in 3 quarters since. The position peaked at $26.4K in Q4 2025. 340 funds tracked by Wall St. Rank hold FBT as of Q2 2026.

Signature Equity Partners held 32 shares of First Trust NYSE Arca Biotechnology Index Fund worth $7.93K as of Q2 2026.
Signature Equity Partners sold 99 First Trust NYSE Arca Biotechnology Index Fund shares in Q2 2026, an estimated $21.3K.
First Trust NYSE Arca Biotechnology Index Fund made up ﹤0.01% of Signature Equity Partners's portfolio in Q2 2026, its #880 holding.
Signature Equity Partners first reported a position in First Trust NYSE Arca Biotechnology Index Fund in Q4 2025 and has held it in 3 quarters since.
Signature Equity Partners's First Trust NYSE Arca Biotechnology Index Fund position peaked at $26.4K in Q4 2025.
340 funds tracked by Wall St. Rank held First Trust NYSE Arca Biotechnology Index Fund as of Q2 2026.

Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.